Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations

  • End date
    Dec 29, 2024
  • participants needed
  • sponsor
    Tianjin Medical University Cancer Institute and Hospital
Updated on 29 July 2021


This is a two-group, parallel, randomized, standard-control phase II study comparing the safety and efficacy of immunotherapy versus standard chemotherapy in patients undergoing T4NX/TXN+ colon cancer surgery with MSI-H or POLE/ POLD1 mutations.This study was conducted in the Department of Gastroenterology, Tumor Hospital of Tianjin Medical University.

Patients with MSI-H or POLE/ POLD1 gene mutations confirmed by PCR sequencing or NGS sequencing will be randomly assigned (2:1) to immunotherapy (experimental group) or standard chemotherapy (control group) after signing informed consent. In this study, 30 patients will be enrolled, 20 patients will receive immunotherapy and 10 patients will receive standard chemotherapy.

In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times. Patients enrolled in this group could enjoy the preferential policy of purchasing 7 times and giving 10 times at their own expense.

The chemotherapy regimen of the standard chemotherapy group was XELOX regimen, oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, orally, bid (half an hour after breakfast and dinner), d1-14, every 21 days. The duration of treatment was determined according to the patient's postoperative pathological stage (3 months for T4N0/ T1-3N1 and 6 months for T4N+/ T1-3N2).

Patients received regular and periodic reviews, with imaging evaluations every 3 months for the first 2 years and every 6 months after 2 years. Safety will be evaluated by AE and laboratory tests. After tumor recurrence or metastasis was first detected, tumor tissue biopsies were taken again for NGS sequencing, and all patients were followed up every 3 months until death according to the plan.

Condition Malignant neoplasm of colon, Colon cancer; rectal cancer, MSI-H, Colorectal Cancer, Adjuvant Therapy, immunotherapies, Immunotherapy, adjunct therapy, adjunctive therapy, Colon Cancer Screening, Colon Cancer, colon carcinoma
Treatment Tirelizumab
Clinical Study IdentifierNCT04969029
SponsorTianjin Medical University Cancer Institute and Hospital
Last Modified on29 July 2021


Yes No Not Sure

Inclusion Criteria

Signed the informed consent
Age 18
Colonic adenocarcinoma confirmed histologically or histopathologically
No residual cancer was confirmed after radical resection of colon cancer
According to the overall postoperative results, T4NX/TXN+ colon cancer was determined according to AJCC/ UICC TNM staging eighth edition
No liver, peritoneum or other distant metastases
MSI-H or POLE/ POLD1 gene mutation was confirmed by PRC or NGS sequencing
ECOG physical status score is 0 or 1
Appropriate organ function according to the following laboratory test values obtained within 7 days prior to use on Day 1 of Cycle 1
Hemoglobin value 9.0g/dL. B. Absolute neutrophil count 1,500/mm3 (1.5 _109/L). C. Platelet count 100,000/mm3 (100_ 109/L). D. Total serum bilirubin 1.5 _upper normal limit (ULN). E. aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) 2.5_ upper limit of normal value (ULN)
Serum creatinine 1.5 times upper limit of normal (ULN) or creatinine clearance 50ml/min
Willing and able to follow research procedures and visit plans

Exclusion Criteria

The patient had received non-surgical treatment for colon cancer (e.g., radiation, chemotherapy, and hormone therapy)
Has a serious illness or medical condition, including but not limited to the
Recurrent in situ or metastatic tumor of any other site is known. B. Systemic active infection (i.e., infection causes body temperature 38). C. Clinically significant intestinal obstruction, pulmonary fibrosis, renal failure, liver failure, or symptomatic cerebrovascular disease
Severe/unstable angina, New York Heart Association (NYHA) grade III or IV symptomatic congestive heart failure
Gastrointestinal bleeding of clinical significance. F. Known presence of human immunodeficiency virus (HIV) or acquired routine immunodeficiency syndrome (AIDS) -associated disease, or active hepatitis B or C
Pregnant or lactating women
The researcher did not consider it appropriate to enter the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note